Cargando…
Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study
AIMS: To assess the efficacy, insulin dose, safety and immunogenicity when people with type 1 diabetes mellitus switched between MYL‐1501D and reference insulin glargine (Lantus®; Sanofi‐Aventis US LLC, Bridgewater, New Jersey). MATERIALS AND METHODS: Eligible participants from INSTRIDE 1 who comple...
Autores principales: | Blevins, Thomas C., Barve, Abhijit, Raiter, Yaron, Aubonnet, Patrick, Athalye, Sandeep, Sun, Bin, Muniz, Rafael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065063/ https://www.ncbi.nlm.nih.gov/pubmed/31691472 http://dx.doi.org/10.1111/dom.13904 |
Ejemplares similares
-
Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies
por: Sun, Bin, et al.
Publicado: (2021) -
Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL‐1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus
por: Heise, Tim, et al.
Publicado: (2019) -
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
por: Hoy, Sheridan M.
Publicado: (2020) -
Correction to: MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
por: Hoy, Sheridan M.
Publicado: (2020) -
Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine
por: Goyal, Parag, et al.
Publicado: (2021)